Page 2 - Eric Elenko News Today

- The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ---------- Rockhopper Exploration PLC - Salisbury, England-based...

Wells Fargo & Company initiated coverage on shares of Karuna Therapeutics (NASDAQ:KRTX – Free Report) in a research report sent to investors on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $225.00 price target on the stock. A number of other research analysts have also recently commented on the stock. JPMorgan Chase […]

Karuna Therapeutics (NASDAQ:KRTX – Free Report) had its price objective decreased by Royal Bank of Canada from $249.00 to $235.00 in a research note published on Friday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock. Several other equities analysts have also recently weighed in on the stock. Morgan Stanley […]

Karuna Therapeutics (NASDAQ:KRTX – Free Report) had its target price cut by Royal Bank of Canada from $249.00 to $235.00 in a research report report published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. KRTX has been the subject of a number of other research reports. HC Wainwright reaffirmed […]

Planning underway for Phase 2 trial of LYT-300 in Fragile X-associated Tremor/Ataxia Syndrome LYT-300 is also being evaluated in a Phase 2a trial for anxiety disorders, and a Phase 2a in patients...

PureTech Health plc has been awarded $11.4 million (£8.9 million) from the US Department of Defense (DoD) to advance its therapeutic candidate for the potential treatment of neurological and neuropsychiatric disorders.

The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- PureTech Health PLC - Boston, US-based biotherapeutics...

A Boston-based biotherapeutics company has announced initiation of a phase 2a proof-of-concept clinical trial of an oral prodrug of endogenous allopregnanolone in healthy volunteers using a validated clinical model of anxiety. According to a release from PureTech Health plc, LYT-300 holds the potential to treat a range of neurological and neuropsychiatric disorders including anxiety disorders and

PureTech Health PLC on Wednesday said that it has started the next stage of trials for LYT-300, in order to test whether the therapy could be used to treat anxiety disorders. The Phase 2a... | June 21, 2023

Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) – Investment analysts at Zacks Research lowered their FY2025 EPS estimates for Karuna Therapeutics in a research note issued on Thursday, June 15th. Zacks Research analyst S. Ganoria now forecasts that the company will earn ($5.07) per share for the year, down from their previous forecast of ($4.81). […]